The Europe bladder cancer diagnostics market was valued at USD 786.10 million in 2023 and is projected to reach USD 1.33 billion by 2030, expanding at a CAGR of 8.38% from 2024 to 2030. This strong growth is primarily driven by continuous technological advancements in noninvasive diagnostics and a growing emphasis on precision-based approaches in managing Non-Muscle Invasive Bladder Cancer (NMIBC). Increasing awareness of early detection, especially for conditions such as Squamous Cell Bladder Cancer, is further supporting the adoption of innovative diagnostic techniques across Europe. The region’s healthcare systems are increasingly prioritizing accuracy, patient comfort, and early intervention factors that collectively enhance diagnosis efficiency and treatment outcomes.

Recent developments in non-invasive diagnostic technologies are revolutionizing bladder cancer detection and monitoring. Traditional methods like cystoscopy and biopsies, although effective, are invasive, costly, and often uncomfortable for patients especially given the high recurrence rate of bladder cancer, which requires long-term surveillance. In contrast, urinary biomarker-based tests and liquid biopsy techniques are providing safer and more convenient alternatives for disease monitoring. These methods help in early detection while minimizing patient discomfort and healthcare costs by reducing the need for repeated invasive procedures.

The market is currently witnessing a high degree of innovation, with several novel tools transforming the diagnostic landscape. A prominent example is Bladder EpiCheck, a non-invasive urine biomarker test that can identify high-grade bladder cancer with high sensitivity and specificity. This technology enables clinicians to detect recurrences earlier and reduce the dependence on frequent cystoscopies. The adoption of such tools is expected to significantly lower healthcare system burdens, improve patient experience, and enhance long-term clinical outcomes by allowing timely therapeutic interventions for high-risk patients.

Key Market Trends & Insights:

  • Germany led the European bladder cancer diagnostics market in 2023, accounting for a substantial 18.94% share, driven by its advanced healthcare infrastructure, strong presence of diagnostic device manufacturers, and increasing bladder cancer awareness initiatives.
  • By technology, the cystoscopy segment held the largest revenue share of 47.54% in 2023, as it remains a standard and reliable diagnostic tool for direct bladder visualization and tissue sampling. However, the “other” segment, which includes MRI, CT scans, AI-based diagnostics, and emerging imaging technologies, is projected to expand at the fastest CAGR of 9.73% during the forecast period due to rapid innovation and growing adoption of precision imaging tools.
  • By cancer type, the transitional cell bladder cancer segment dominated with a market share of 87.39% in 2023, reflecting its high prevalence across Europe. Meanwhile, the squamous cell carcinoma (SCC) segment is expected to witness faster growth as awareness and early screening improve, driving demand for specialized diagnostic methods.
  • By end use, hospital settings accounted for the largest share of 75.51% in 2023, owing to their access to advanced diagnostic infrastructure and multidisciplinary expertise. However, non-hospital settings, including specialty clinics, ambulatory surgical centers, and cancer treatment centers, are anticipated to grow at a notably faster pace as these facilities become increasingly equipped with modern diagnostic technologies and offer patient-centric, cost-effective care options.

Order a free sample PDF of the Europe Bladder Cancer Diagnostics Market Intelligence Study, published by Grand View Research.

Key Players

  • Abbott
  • Nucleix
  • Danaher Corporation
  • Pacific Edge
  • Polymedco, LLC.
  • KARL STORZ
  • AroCell (IDL Biotech)
  • Micromedic Technologies
  • Sysmex Corporation.
  • Vesica Health

Recent Developments

  • In November 2023, Nucleix announced that it would receive national reimbursement approval from The Dutch Healthcare Authority (NZA) in the Netherlands, effective January 1, 2024, for its CE-marked Bladder EpiCheck test. This test is used for detecting primary or recurrent bladder cancer and UTUC. The NZA's decision underscores the commitment to advancing innovation for this underserved cancer in the Netherlands. Nucleix continues to work towards achieving national reimbursement in other European countries.
  • In September 2022, the latest KARL STORZ Blue Light Cystoscopy system was prominently showcased at the E-Masterclass in Urology. This advanced system enhanced the detection and management of bladder cancer by utilizing innovative imaging technology to improve tumor visualization and treatment outcomes.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the Europe bladder cancer diagnostics market is undergoing a significant transformation driven by technological innovation and the growing adoption of non-invasive testing solutions. The rising incidence of bladder cancer, combined with the need for less intrusive and more accurate diagnostic procedures, continues to propel market expansion. Advanced tools such as Bladder EpiCheck are redefining early detection and patient monitoring, thereby improving treatment outcomes and reducing healthcare burdens. With strong support from healthcare institutions, innovation hubs, and key regional players, Europe is positioned to remain a leading center for advanced bladder cancer diagnostics over the coming years.